期刊
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
卷 61, 期 9, 页码 404-409出版社
DUSTRI-VERLAG DR KARL FEISTLE
DOI: 10.5414/CP204444
关键词
palindromic rheumatism; iguratimod; anti-inflammatory
This study reports the first use of iguratimod, a novel small-molecule compound with anti-inflammatory effects, in the treatment of refractory palindromic rheumatism (PR). The use of iguratimod significantly improved pain symptoms and reduced flare frequency, although there were some adverse effects observed after treatment discontinuation. Iguratimod provides a new treatment option for patients with refractory PR.
Objective: Palindromic rheumatism (PR) is characterized by interstitial inflammation, redness, and pain in joints and periarticular tissues. However, the pathogenesis and treatment of PR remain unknown. Herein, we report on the first use of iguratimod (IGU) - a novel small-molecule compound with anti-inflammatory effects - in the treatment of refractory PR. Case: A male patient aged 70 years was diagnosed with PR based on medical history, clinical manifestations, and ultrasound findings. The patient was treated with IGU (25 mg PO q.d.). The disease activity was measured by the frequency of PR flares and clinical symptoms. The patient's laboratory tests were monitored for safety reasons. Results: The use of IGU significantly improved pain symptoms and reduced flare frequency. After 28 days of treatment, abnormal levels of glutamic-pyruvic transaminase were observed. One month after discontinuation of IGU, flares occurred in the patient's second toe of both feet. Conclusion: IGU provides a new treatment option for patients with refractory PR who cannot use hydroxychloroquine. The effective treatment with IGU suggests the potential pathogenesis of PR and provides a basis for physicians to choose a new drug for PR treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据